More importantly, the elimination of HER2 or HER3 receptors in cetuximab-resistant HNC cells has no effect on EGFR phosphorylation, whereas AXL knockdown causes a prominent decrease in EGFR activity and significant inhibition of tumor proliferation. Here, ERBB2 is linked to neoplasm.